A clinical trial to study the effects of a drug Ketamine ,in treatment of patients with depression.

Comparative efficacy of oral Ketamine vs. Electroconvulsive therapy in moderate to severe depression: A randomized controlled trial. - ECT-KETAMINE RCT

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/01/060984

Enrollment

Registered

2024-01-01

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F321- Major depressive disorder, singleepisode, moderate Health Condition 2: F322- Major depressive disorder, singleepisode, severe without psychotic features Health Condition 3: F331- Major depressive disorder, recurrent, moderate

Interventions

Intervention1: Ketamine: Oral ketamine 150 175 mg, administered thrice weekly (alternate days) for 2 weeks Route Oral Control Intervention1: Bitemporal Electroconvulsive Therapy: Dose of Charge As per

Eligibility

Inclusion criteria

Inclusion criteria: All patients coming for treatment at the OPD and IPD of the Department of Psychiatry fulfilling the following are included: a) People with Moderate to Severe Depressive episode according to criteria in DSM 5 and ICD 10 RCD. b) Aged between 18 to 65 years c) American Society of Anaesthesiologists (ASA) score of 1, 2 or stable 3 d) With Informed consent from the Legally Authorised Relative

Exclusion criteria

Exclusion criteria: a. Severe hepatic or renal impairment b. Uncontrolled hypertension, history of significant cardiac arrhythmias, history of substance dependence, history of seizure disorder or organic brain disorder, pregnancy or breastfeeding c. Concomitant psychotic disorder. d. Non-Consenting e. History of ketamine allergy f. Receipt of ECT or ketamine in the past 6 months.

Design outcomes

Primary

Measure	Time frame
change in MADRS scoreTimepoint: baseline and one week after completion of final intervention (Week 3)	—

Secondary

Measure	Time frame
To compare MADRS scores between ECT and ketamine groupsTimepoint: Base line 1 and 2 weeks;compare MADRS response and remission ratesTimepoint: Base line 1 and 2 weeks	—

Countries

India

Contacts

Public ContactZafar Mahmood

AIIMS Bhubaneswar

psych_susanta@aiimsbhubaneswar.edu.in09801801184

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026